My Fund Comparison
Initilizing list...
|
Tekla Life Sciences Investors as of
06/30/2022
| NYSE /
HQL |
Asset Class:
Sector Equity Funds
|
1 YR Lipper Avg:
N/A* |
| Growth of $10K |
|
| Avg Annual Total Return % |
| |
10 YR |
5 YR |
1 YR |
YTD |
| Market Return |
9.00% |
1.34% |
-27.51% |
-22.39% |
| Lipper Pct. Rank |
46 |
80 |
58 |
58 |
|
| NAV Return |
9.37% |
2.53% |
-22.38% |
-17.67% |
| Lipper Pct. Rank |
50 |
79 |
70 |
66 |
| Premium/Discount History |
|
| Premium/Discount |
| 10 YR Avg |
5 YR Avg |
YTD Avg |
|
-3.914% |
-5.714% |
-2.230% |
|
| NAV |
$15.43 |
Market Price |
$14.23 |
| Net Change |
-$0.16 |
Market Change |
-$0.12 |
| Premium/Discount |
-7.78% |
| 1 YR NAV Return |
-22.385% |
| 1 YR NAV Rank |
70 |
| 12-Mo Yield as of
5/31/2022 |
Yield
Def |
| Income Only Yield |
0.00% |
| Distribution Yield (Market) |
10.91% |
| Most Recent Income Dividend |
$0.370 |
| Ex-Div Date |
4/21/2016 |
| Most Recent Cap Gain Dividend |
$0.350 |
| Ex-Div Date |
5/26/2022 |
| Dividend Frequency |
Annually |
| YTD Dividends |
-- |
| YTD Capital Gains |
$0.740 |
| Inception Date |
5/8/1992 |
| Fund Advisor |
Tekla Capital Management LLC |
| Manager & Tenure |
Team Managed |
| Phone |
800-451-2597 |
| Website |
www.teklacap.com |
| Total Net Assets (mil)
as of
6/30/2022 |
$392.2 |
| % Leveraged Assets
as of
9/30/2021 |
-- |
| Portfolio Turnover |
62.00% |
| Mgmt Fees |
1.018% |
| Expense Ratio |
1.240% |
| Fund Objective |
| The Fund seeks long-term capital appreciation by investing primarily in equity and related securities of U.S. and foreign companies principally engaged in the development, production or distribution of products or services related to scientific advances in health care, agriculture and environmental management. |
|
| Top Holdings
(as of 3/31/2022) |
|
Amgen Inc ORD |
8.33% |
|
Regeneron Pharmaceuticals Inc ORD |
7.21% |
|
Gilead Sciences Inc ORD |
7.01% |
|
Vertex Pharmaceuticals Inc ORD |
5.73% |
|
Illumina Inc ORD |
5.17% |
|
Horizon Therapeutics PLC ORD |
4.92% |
|
Seagen Inc ORD |
4.00% |
|
Moderna Inc ORD |
3.83% |
|
Alnylam Pharmaceuticals Inc ORD |
2.50% |
|
State Street US Government Money Market Fund;Inst |
1.95% |
|
| Top Sectors
(as of 3/31/2022) |
|
Health Care |
83.26% |
|
Non Classified Equity |
13.75% |
|
*1 YR Lipper Average not available for this fund.
|
Resources
Aberdeen Closed-End TV
Asset TV — CEF Channel
CEF Connect
Cohen & Steers CEFs Knowledge Center
Harvest — CEFA Channel
Legg Mason CEFs
Seeking Alpha — CEFA Channel
|
|
Powered by a SySys® data & content management system.
© Thomson Reuters 2019. All rights reserved. Any copying, republication or redistribution of Lipper, a Thomson Reuters company, content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper, a Thomson Reuters company. Lipper, a Thomson Reuters company shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
|